Monitor the shareholder vote and regulatory approvals, as the deal's accretive nature and portfolio expansion make it a significant positive catalyst for Ligand; watch for integration updates and any changes to the litigation outcome that could affect the CVR value.
Price Chart
Executive Summary
Ligand Pharmaceuticals (LGND) is acquiring XOMA Royalty Corporation in a cash deal worth $39.00 per share, totaling approximately $739 million in equity value. The transaction, expected to close in Q3 2026, is immediately accretive to Ligand's earnings and expands its royalty portfolio with seven new commercial products, including VABYSMO and OJEMDA. XOMA Royalty shareholders will also receive a contingent value right (CVR) for potential future proceeds from ongoing litigation with Janssen Biotech.
Key Financial Metrics
Key Facts
- Ligand is acquiring XOMA Royalty for $39.00 per share in cash, a 14% premium to its 30-day VWAP.
- The total equity value of the deal is approximately $739 million.
- XOMA Royalty shareholders will receive one non-transferable Contingent Value Right (CVR) per share, entitling them to 75% of net proceeds from the Janssen litigation.
- The acquisition adds seven new commercial products and over 100 development-stage assets to Ligand's portfolio.
- The deal is expected to be immediately accretive to Ligand's adjusted EPS and close in Q3 2026.
- Ligand's 2026 adjusted EPS guidance has been raised to $8.50-$9.50, with an expected $1.50 per share accretion in 2027.
Financial Impact
Approximately $739 million in equity value, with $39.00 per share in cash and a CVR for potential future litigation proceeds.
Risk Factors
- The deal is subject to customary closing conditions, including XOMA Royalty stockholder approval and regulatory clearances, which could delay or prevent the transaction.
- The value of the CVR is contingent on the outcome of the Janssen litigation, which is uncertain and could result in no proceeds for shareholders.
- Integration risks could arise from combining the two companies' operations and portfolios.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-179652 |
| Document: 0001193125-26-179652-index-headers.html | 0001193125-26-179652 |
| Document: 0001193125-26-179652-index.html | 0001193125-26-179652 |
| Document: 0001193125-26-179652.txt | 0001193125-26-179652 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 18, 2026 23w ago | DEFA14A | — | awaiting T+5 | — | — |
May 18, 2026 23w ago | 8-K | — | awaiting T+5 | — | — |
Apr 30, 2026 25w ago | 8-K | — | awaiting T+5 | — | — |
Apr 27, 2026 26w ago | DEFA14A | $0.0400 $0.0500 | ▲ +25.00% | ▲ +24.32% | — |
Apr 27, 2026 26w ago | 8-K | $0.0400 $0.0500 | ▲ +25.00% | ▲ +24.32% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers